Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III comparison of Dopram (doxapram hydrochloride) vs Caffeine Cooper (caffeine citrate) for treatment of apnea in premature infants
2007-002567-27Phase 3Completed
- Sponsor
- RIEMSER
- Start
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of doxapram in apnea of prematurity (AOP) (2 arms), sponsored by RIEMSER. Primary endpoint: Primary efficacy endpoint. Started May 2009; status: completed.
02
Drugs
doxapram
03
Conditions
apnea of prematurity (AOP)
Beyond the preview
Go deeper on 2007-002567-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002567-27.